Utomo Nugroho B, Mochtar Chaidir A, Umbas Rainy
Department of Urology, University of Indonesia-dr. Cipto Mangunkusumo Hospital, Indonesia.
Acta Med Indones. 2012 Jan;44(1):10-5.
to evaluate the effectiveness of primary hormonal treatment on localized and locally advanced prostate cancer, including the analysis on the survival predictive factors.
patients with localized (T1,T2N0M0) and locally advanced (T3, T4N0M0) prostate cancer who had received primary hormonal treatment between January 1995 and December 2009 were evaluated retrospectively based on their specific medical records at Department of Urology in Cipto Mangunkusumo Hospital (RSCM) and Dharmais Cancer Hospital (RSKD).
about 79 (29.9%) of 264 patients with localized and advanced local prostate cancer received primary hormonal treatment. In the localized prostate cancer group, mean survival was 58.3 months (range: 1.87-170.78) and 5-year survival was 77.3%; while in locally advanced prostate cancer patients, mean survival was 40.87 months (range 7.29-115.29) and 5-year survival was only 22.7%. Hemoglobin level was a significant clinical parameter of survival predictive factors for both localized and locally advanced prostate cancer groups. The lower the hemoglobin level, the survival will be shorter.
there were no significant differences between mean survival and 5-year survival rate, between localized and locally advanced prostate cancer patients who had received primary hormonal treatment. Hemoglobin level is survival predictive factors for localized and locally advanced prostate cancer patients.
评估一线激素治疗对局限性及局部晚期前列腺癌的有效性，包括对生存预测因素的分析。
回顾性评估1995年1月至2009年12月期间在西爪哇省芝多龙古苏莫医院（RSCM）和达玛伊斯癌症医院（RSKD）泌尿外科接受一线激素治疗的局限性（T1、T2N0M0）和局部晚期（T3、T4N0M0）前列腺癌患者的特定病历。
264例局限性和局部晚期前列腺癌患者中约79例（29.9%）接受了一线激素治疗。在局限性前列腺癌组中，平均生存期为58.3个月（范围：1.87 - 170.78个月），5年生存率为77.3%；而在局部晚期前列腺癌患者中，平均生存期为40.87个月（范围7.29 - 115.29个月），5年生存率仅为22.7%。血红蛋白水平是局限性和局部晚期前列腺癌组生存预测因素的一个重要临床参数。血红蛋白水平越低，生存期越短。
接受一线激素治疗的局限性和局部晚期前列腺癌患者的平均生存期和5年生存率之间无显著差异。血红蛋白水平是局限性和局部晚期前列腺癌患者的生存预测因素。
